Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial.
Remington G, Kapur S, Foussias G, Agid O, Mann S, Borlido C, Richards S, Javaid N.
J Clin Psychopharmacol. 2012 Feb;32(1):95-9.
Related citations
Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia.
Buchanan RW, Panagides J, Zhao J, Phiri P, den Hollander W, Ha X, Kouassi A, Alphs L, Schooler N, Szegedi A, Cazorla P.
J Clin Psychopharmacol. 2012 Feb;32(1):36-45.
Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
Miura I, Takeuchi S, Katsumi A, Mori A, Kanno K, Yang Q, Mashiko H, Numata Y, Niwa S.
J Clin Psychopharmacol. 2012 Feb;32(1):106-9.
Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?
Jürgens G, Rasmussen HB, Werge T, Dalhoff K, Nordentoft M, Andersen SE.
J Clin Psychopharmacol. 2012 Feb;32(1):100-5.
All-cause mortality and medication risk factors in schizophrenia: a prospective cohort study.
Tenback D, Pijl B, Smeets H, Os Jv, Harten Pv.
J Clin Psychopharmacol. 2012 Feb;32(1):31-5.
Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia.
Lin SK, Chen CK, Liu YL.
J Clin Psychopharmacol. 2011 Dec;31(6):758-62.
Polymorphisms of INSIG2, MC4R, and LEP are associated with obesity- and metabolic-related traits in schizophrenic patients.
Kuo PH, Kao CF, Chen PY, Chen CH, Tsai YS, Lu ML, Huang MC.
J Clin Psychopharmacol. 2011 Dec;31(6):705-11.
Using ketamine to model semantic deficits in schizophrenia.
Neill E, Rossell SL, McDonald S, Joshua N, Jansen N, Morgan CJ.
J Clin Psychopharmacol. 2011 Dec;31(6):690-7.
A cytochrome P450 inhibitor in a stable schizophrenic patient: a drug interaction.
Kumar D, Muppa M, Kablinger A.
J Clin Psychopharmacol. 2011 Oct;31(5):670-1. No abstract available.
Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia: a 4-year follow-up naturalistic study.
Altamura AC, Buoli M, Mauri MC.
J Clin Psychopharmacol. 2011 Oct;31(5):661-3. No abstract available.
Ibogaine-associated psychosis in schizophrenia: a case report.
Houenou J, Homri W, Leboyer M, Drancourt N.
J Clin Psychopharmacol. 2011 Oct;31(5):659. No abstract available.
Effects of add-on cilostazol on cognition in patients with schizophrenia: an open-label pilot trial.
Shirayama Y, Konishi T, Hashimoto K.
J Clin Psychopharmacol. 2011 Oct;31(5):659-61. No abstract available.
Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia.
Borba CP, Fan X, Copeland PM, Paiva A, Freudenreich O, Henderson DC.
J Clin Psychopharmacol. 2011 Oct;31(5):653-8.
Carnitine supplementation for valproate-related hyperammonemia to maintain therapeutic valproate level.
Sonik P, Hilty DM, Rossaro L, Bourgeois JA.
J Clin Psychopharmacol. 2011 Oct;31(5):680-2. No abstract available.
Hyperosmolar hyperglycemic state associated with ziprasidone treatment: a case report.
Létourneau G, Abdel-Baki A, Dubreucq S, Mahone M, Granger B.
J Clin Psychopharmacol. 2011 Oct;31(5):671-3. No abstract available.
A self-limiting case of atypical neuroleptic malignant syndrome associated with zotepine.
Hsu WC, Lin ST, Chen CC, Tsang HY, Huang MF.
J Clin Psychopharmacol. 2011 Oct;31(5):667-9. No abstract available.
Late-onset agranulocytosis in a patient treated with clozapine and lamotrigine.
Tourian L, Margolese HC.
J Clin Psychopharmacol. 2011 Oct;31(5):665-7. No abstract available.
Antipsychotic drugs increase adipose stem cell differentiation--implications for treatment with antipsychotic drugs.
Hemmrich K, Kappel BA, Paul NE, Goy D, Luckhaus C, Pallua N, Fehsel K.
J Clin Psychopharmacol. 2011 Oct;31(5):663-5. No abstract available.
Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone.
Yasui-Furukori N, Tsuchimine S, Saito M, Nakagami T, Sugawara N, Fujii A, Kaneko S.
J Clin Psychopharmacol. 2011 Oct;31(5):633-7.
Changes in the metabolic parameters and QTc interval after switching from olanzapine to aripiprazole in Japanese patients with stable schizophrenia.
Suzuki Y, Sugai T, Ono S, Sawamura K, Fukui N, Watanabe J, Tsuneyama N, Someya T.
J Clin Psychopharmacol. 2011 Aug;31(4):526-8. No abstract available.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on